Crescita Therapeutics Inc
TSX:CTX

Watchlist Manager
Crescita Therapeutics Inc Logo
Crescita Therapeutics Inc
TSX:CTX
Watchlist
Price: 0.45 CAD Market Closed
Market Cap: 8.4m CAD

Intrinsic Value

CTX doesn't have a meaningful market cap.

The intrinsic value of one CTX stock under the Base Case scenario is 0.6 CAD. Compared to the current market price of 0.45 CAD, Crescita Therapeutics Inc is Undervalued by 25%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CTX Intrinsic Value
0.6 CAD
Undervaluation 25%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Crescita Therapeutics Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about CTX?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is CTX valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Crescita Therapeutics Inc.

Explain Valuation
Compare CTX to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CTX?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Crescita Therapeutics Inc

Current Assets 16m
Cash & Short-Term Investments 8.3m
Receivables 1.9m
Other Current Assets 5.8m
Non-Current Assets 5.5m
PP&E 2.1m
Intangibles 1.6m
Other Non-Current Assets 1.7m
Current Liabilities 5.1m
Accounts Payable 4.6m
Other Current Liabilities 534k
Non-Current Liabilities 79k
Other Non-Current Liabilities 79k
Efficiency

Free Cash Flow Analysis
Crescita Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Crescita Therapeutics Inc

Revenue
22.1m CAD
Cost of Revenue
-10.6m CAD
Gross Profit
11.4m CAD
Operating Expenses
-12.3m CAD
Operating Income
-909k CAD
Other Expenses
1.4m CAD
Net Income
457k CAD
Fundamental Scores

CTX Profitability Score
Profitability Due Diligence

Crescita Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin
Strong 3Y Average Gross Margin
Declining Net Margin
Declining ROE
30/100
Profitability
Score

Crescita Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

CTX Solvency Score
Solvency Due Diligence

Crescita Therapeutics Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Low D/E
Short-Term Solvency
Low Altman Z-Score
47/100
Solvency
Score

Crescita Therapeutics Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CTX Price Targets Summary
Crescita Therapeutics Inc

There are no price targets for CTX.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Crescita Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for CTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one CTX stock?

The intrinsic value of one CTX stock under the Base Case scenario is 0.6 CAD.

Is CTX stock undervalued or overvalued?

Compared to the current market price of 0.45 CAD, Crescita Therapeutics Inc is Undervalued by 25%.

Back to Top